登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《MedRxiv，3月6日，Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-07

  • Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

    Bo Diao, Zeqing Feng, Chenhui Wang, Huiming Wang, Liang Liu, Changsong Wang, Rongshuai Wang, Ying Liu, Yueping Liu, Gang Wang, Zilin Yuan, Yuzhang Wu, Yongwen Chen

    doi: https://doi.org/10.1101/2020.03.04.20031120

    Abstract

    BACKGROUND The coronavirus disease 2019 (COVID-19) is a newly emerged infection from the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Apart from the respiratory system, it is unclear whether SARS-CoV-2 can also directly infect other tissues such as the kidney or induce acute renal failure. METHODS We conducted a retrospective analysis of estimated glomerular filtration rate (eGFR), plasma creatinine, and urea concentrations along with other clinical parameters from 85 patients with laboratory-confirmed COVID-19 admitted to a hospital in Wuhan from January 17, 2020 to March 3, 2020.

    *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.

  • 原文来源：https://www.medrxiv.org/content/10.1101/2020.03.04.20031120v1
67浏览量
原文链接
相关报告

  • 《MedRxiv，3月8日，A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-09
    • A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients Lei Liu, Wanbing Liu, Shengdian Wang, Shangen Zheng doi: https://doi.org/10.1101/2020.03.06.20031856 Abstract Background The outbreak of the recently emerged novel corona virus disease 2019 (COVID-19) poses a challenge for public health laboratories. We aimed to evaluate the diagnostic value of serological assay for SARS-CoV-2. Methods A newly-developed ELISA assay for IgM and IgG antibodies against N protein of SARS-CoV-2 were used to screen the serums of 238 admitted hospital patients with confirmed or suspected SARS-CoV-2 infection from February 6 to February 14, 2020. SARS-CoV-2 RNA was detected by real time RT-PCR on pharyngeal swab specimens. Findings Of the 238 patients, 194 (81.5%) were detected to be antibody (IgM and/or IgG) positive, which was significantly higher than the positive rate of viral RNA (64.3%). *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    92浏览量
    原文链接

  • 《bioRxiv，6月6日，Synthetic Antibodies neutralize SARS-CoV-2 infection of mammalian cells》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-06-09
    • Synthetic Antibodies neutralize SARS-CoV-2 infection of mammalian cells Shane Miersch, Mart Ustav, Zhijie Li, James B. Case, Safder Ganaie, Giulia Matusali, Francesca Colavita, Daniele Lapa, Maria R. Capobianchi, View ORCID ProfileGuiseppe Novelli, Jang B. Gupta, Suresh Jain, Pier Paolo Pandolfi, Michael S. Diamond, Gaya Amarasinghe, James M. Rini, Sachdev S. Sidhu doi: https://doi.org/10.1101/2020.06.05.137349 Abstract Coronaviruses (CoV) are a large family of enveloped, RNA viruses that circulate in mammals and birds but have crossed the species barrier to infect humans seven times. Of these, three pathogenic strains have caused zoonotic infections in humans that result in severe respiratory syndromes including the Middle East Respiratory Syndrome (MERS-CoV), severe acute respiratory syndrome (SARS-CoV), and now SARS-CoV-2 coronaviruses, the latter of which is the cause of the ongoing pandemic of coronavirus disease 2019 (COVID-19). Here, we describe a panel of synthetic monoclonal antibodies, built on a human framework, that bind SARS-CoV-2 spike protein, compete for binding with ACE2, and potently inhibit infection by SARS-CoV-2. These antibodies were found to have a range of neutralization potencies against live virus infection in Vero E6 cells, potently inhibiting authentic SARS-CoV-2 virus at sub-nanomolar concentrations. These antibodies represent strong immunotherapeutic candidates for treatment of COVID-19. Competing Interest Statement S.S, P.P.P and S.J, are cofounders of Virna Therapeutics. The company is developing novel therapies for COVID-19 and other viruses.
    168浏览量
    原文链接